Last reviewed · How we verify
Experimental: Rivaroxaban monotherapy
Rivaroxaban monotherapy, developed by the Chinese Academy of Medical Sciences, Fuwai Hospital, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by its mechanism and primary indication, though specific details are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Experimental: Rivaroxaban monotherapy |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: